Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 12Withdrawn 5Unknown 5Recruiting 4Not yet recruiting 3Active not recruiting 3Terminated 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 2Gynecologic 1

Conditions

Small Cell Lung Carcinoma 4Uterine Cervical Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Recurrence 2Stomach Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Metastatic Solid Tumors 1Glioblastoma 1Endometrial Neoplasms 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Neoplasms 1Cholangiocarcinoma 1Ann Arbor Stage II Mantle Cell Lymphoma 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 34Pemetrexed 27Drug Therapy 22Cisplatin 22osimertinib 18aflutinib 11Paclitaxel 11pembrolizumab 10Surgical Procedures, Operative 10Docetaxel 10tislelizumab 9Radiotherapy 8Magnetic Resonance Spectroscopy 8anlotinib 7Specimen Handling 7Bevacizumab 7130-nm albumin-bound paclitaxel 7toripalimab 6cemiplimab 6Immunotherapy 6sintilimab 5ensartinib 5durvalumab 5Radiosurgery 5Platinum Compounds 5Nivolumab 5trametinib 4aumolertinib 4Observation 4Injections 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Carcinoma, Non-Small-Cell Lung × Platinum × Clear all
NCT07453394 2026-03-06

QLS5132 Combination Therapy in Advanced Solid Tumors

Qilu Pharmaceutical Co., Ltd.

Phase 1/2 Not yet recruiting
626 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT06963502 2025-05-09

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 1 Not yet recruiting
762 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT06142617 2023-11-21

A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.

Peking Union Medical College Hospital

Phase 2 Not yet recruiting
37 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡